LTBR and synovial sarcoma: However, a phase II trial showed that the baminercept, a lymphotoxin β receptor IgG fusion protein, blocks lymphotoxin β receptor signaling while failing to significantly improve glandular and extraglandular disease in patients with primary SS (St Clair et al., 2018).